Covid-19 and Diabetes in West of Algeria (COVIDIAB-13)

Prevalence of Diabetes Among Hospitalized Patients With Covid-19 in West of Algeria. Identification of Diabetes-related Associated Factors Severe Forms

By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019). This exponential pandemic coronavirus infection is responsible for severe forms in 15 to 20%, for critical ill requiring ventilation in 5% and for mortality in 2%. Algeria was part of the 13 top priority countries identified by WHO based on their direct links and volume of travel to the infected provinces in China.

It is known that some predisposing conditions lead to a worse outcome with coronavirus.

In China, the overall case-fatality rate was 2.3%, but was higher in patients with diabetes (7.3%). In Italy, the most common comorbidities associated with death from COVID-19 were hypertension (73.8%) and diabetes (33.9%). The US Centers for Disease Control and Prevention suggests diabetes is the most common comorbidity in COVID-19 cases. In the largest cohort NHS England study, death from COVID-19 was strongly associated with uncontrolled diabetes (after full adjustment, HR 2.36).

The West Algerian CORODIAB-13 study aims is (1) to assess the prevalence of diabetes among hospitalized patients with Covid-19, (2) to describe the phenotypic characteristics of patients with diabetes, and (3) to identify the parameters specific to the diabetic which are associated with severe forms.

In the future, this study will provide answers for two main questions

1. Why diabetics are more at risk of developing Covid-19 infection?
2. Why diabetics are at high risk of developing severe forms?

Study Overview

• Status: Unknown
• Conditions: Severe Acute Respiratory Syndrome; Coronavirus Infections; Diabetes Mellitus; Prevalence; Risk Factors; Patient Outcome Assessment
• Intervention / Treatment: Drug: MANAGEMENT OF COVID-19

• Study Type: Observational
• Enrollment (Anticipated): 100

Contacts and Locations

Study Locations

• Algeria
  • Tlemcen, Algeria, 130000
    • Recruiting
    • Department of Internal Medicine, Acedemic Hospital of Tlemcen
    • Contact: ALI LOUNICI, Professor; Phone Number: 00213667314275; Email: ali.lounici@univ-tlemcen.dz
    • Sub-Investigator: Benattou ZIANE, Professor
    • Sub-Investigator: Samia BENCHOUK, Professor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Adults diabetic patients with COVID-19 infection admitted in academic hospital of Tlemcen (Algeria).

Description

Inclusion Criteria:

• Patients admitted in a hospital center since 1th April 2020
• Patients with COVID19 with biological proof (specific PCR) or with clinical and radiological diagnosis.
• Patient with diabetes known before the admission
• New onset diabetes discovered at admission (plasma glycaemia value strictly greater than 2 g/l at any time)

Exclusion Criteria:

• Pregnant
• Active Cancer
• Dementia
• Minors, adults under guardianship, protected persons
• Significant disability (The Modified Rankin Scale more than 2 prior admission)

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of diabetes among all hospitalized COVID-19	Assess the prevalence of diabetes among hospitalized patients with Covid-19 in Area of Tlemcen	3 months
Diabetes-related factors risk	Describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19	3 months

Collaborators and Investigators

• Sponsor: Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen
• Collaborators: ATRSS, DGRST, Algeria

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2020
• Primary Completion (Anticipated): June 30, 2020
• Study Completion (Anticipated): June 30, 2020

Study Registration Dates

• First Submitted: June 1, 2020
• First Submitted That Met QC Criteria: June 1, 2020
• First Posted (Actual): June 2, 2020

Study Record Updates

• Last Update Posted (Actual): June 2, 2020
• Last Update Submitted That Met QC Criteria: June 1, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Keywords: COVID-19; DIABETES; OUTCOMES; RISK FACTORS; SEVERE ILLNESS
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Endocrine System Diseases; Severe Acute Respiratory Syndrome; COVID-19; Coronavirus Infections; Diabetes Mellitus
• Other Study ID Numbers: COVIDIAB-13

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No